Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Axsome Therapeutics, Inc. (AXSM : NSDQ)

• Company Description    Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available. Number of Employees: 925

• Price / Volume Information    Yesterday's Closing Price: $145.04 Daily Weekly Monthly 20 Day Moving Average: 911,736 shares Shares Outstanding: 52.38 (millions) Market Capitalization: $7,597.34 (millions) Beta: 0.86 52 Week High: $257.93 52 Week Low: $123.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -26.01% -25.23% 12 Week -38.19% -39.69% Year To Date -20.59% -23.67%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL One World Trade Center 22nd Floor - NEW YORK,NY 10007 USA ph: 212-332-3241 fax: 212-320-0245 None http://www.axsome.com

• General Corporate Information    Officers Herriot Tabuteau - Chief Executive Officer and Chairman Nick Pizzie - Chief Financial Officer Roger Jeffs - Director Mark Coleman - Director Mark Saad - Director Peer Information Axsome Therapeutics, Inc. (CORR.) Axsome Therapeutics, Inc. (RSPI) Axsome Therapeutics, Inc. (CGXP) Axsome Therapeutics, Inc. (BGEN) Axsome Therapeutics, Inc. (GTBP) Axsome Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 05464T104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/02/26 Share - Related Items Shares Outstanding: 52.38 Most Recent Split Date: (:1) Beta: 0.86 Market Capitalization: $7,597.34 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.96 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/02/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 89.60 Price/Cash Flow: - Price / Sales: 9.78 EPS Growth vs. Year Ago Period: -7.61% vs. Previous Quarter: 21.43% Sales Growth vs. Year Ago Period: 45.54% vs. Previous Quarter: 14.21% ROE 09/30/26 - - 06/30/26 - -265.55 03/31/26 - -267.16 ROA 09/30/26 - - 06/30/26 - -28.10 03/31/26 - -28.53 Current Ratio 09/30/26 - - 06/30/26 - 1.43 03/31/26 - 1.39 Quick Ratio 09/30/26 - - 06/30/26 - 1.34 03/31/26 - 1.32 Operating Margin 09/30/26 - - 06/30/26 - -25.64 03/31/26 - -27.32 Net Margin 09/30/26 - - 06/30/26 - -24.68 03/31/26 - -26.59 Pre-Tax Margin 09/30/26 - - 06/30/26 - -24.61 03/31/26 - -26.66 Book Value 09/30/26 - - 06/30/26 - 1.62 03/31/26 - 1.06 Inventory Turnover 09/30/26 - - 06/30/26 - 1.74 03/31/26 - 2.06 Debt-to-Equity 09/30/26 - - 06/30/26 - 1.52 03/31/26 - 2.27 Debt-to-Capital 09/30/26 - - 06/30/26 - 60.39 03/31/26 - 69.38

Powered by Zacks Investment Research ©